相关实验视频

Updated: Jan 9, 2026

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

尼莫图祖马布加根西塔基辅助化疗用于可切除的胰腺癌:一项回顾性观察性研究

Siyi Zou¹, Chenlei Wen¹, Fanlu Li¹

¹Department of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine.

|December 8, 2025

概括

在可切除胰腺癌 (RPC) 的辅助化疗 (AC) 中添加尼莫图祖马布,显示了生存效益趋势. 这种组合证明了长时间的整体存活率 (OS) 和无病存活率 (DFS),具有良好的安全性.

科学领域:

在瘤学瘤学.
医学研究医学研究

背景情况:

辅助化疗 (AC) 在R0/R1切除后改善了可切除胰腺癌 (RPC) 的存活率,但存在局限性.
在利用大分子向药物 (如尼莫图祖马布) 与AC一起,存在一个差距.

研究的目的:

在RPC患者中研究添加尼莫图祖马布到AC的疗效和安全性.
评估对整体生存期 (OS) 和无病生存期 (DFS) 的影响.

主要方法:

一项对RPC患者进行了回顾性研究,这些患者接受了手术和AC治疗,有或没有nimotuzumab.
从2016年5月到2022年7月收集的数据,重点是OS,DFS和不良事件.
探索性分析包括KRAS突变和KRASG12D亚型.

主要成果:

研究组 (AC + nimotuzumab) 与对照组 (单独AC) 相比,显示了延长mOS (45.1 vs. 28.1个月) 和mDFS (20.0 vs. 13.0个月) 的趋势.
在KRAS突变和KRASG12D亚组中观察到生存益处,在KRASG12D的R0患者中显著的DFS益处 (P=0.022).
副作用主要是轻微的血液学异常;没有发生4级或更高的反应.

结论:

将尼莫图祖马布添加到基于凝胺的AC疗程中,为RPC患者提供了生存益处的趋势.
组合治疗表明了令人满意的安全性.

关键词:

辅助性化疗是一种辅助性化疗.尼莫图祖马巴姆 (Nimotuzumab) 是一个可切除的胰腺癌.

更多相关视频

Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction

Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction

Published on: January 3, 2020

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...